KATIE MCGILL: Open Payments
NPI 1972912202 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$933 in 45 payments from 18 companies in 2025. Trend: 2023 $527 · 2024 $674 · 2025 $933
Food & beverage: $933
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $305 |
| Insmed, Inc. | 5 | $115 |
| JAZZ PHARMACEUTICALS INC. | 6 | $103 |
| Viatris Specialty LLC | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Verona Pharma, Inc. | 2 | $37 |
| GENZYME CORPORATION | 2 | $35 |
| Novo Nordisk Inc | 1 | $34 |
| Merck Sharp & Dohme LLC | 1 | $32 |
| Lilly USA, LLC | 2 | $29 |
Products named: TEZSPIRE, FASENRA, Arikayce, XYWAV, DUPIXENT, YUPELRI, Ohtuvayre, Wegovy.
Industry payments across NE — which companies pay providers there.
